Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | SVP, Chief Scientific Officer | October 04, 2021 | October 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date October 04, 2021 · Filed October 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,789 |
Ending reported balance
After 2021-10-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-10-04 · Exercise / conversion · Acquired 1,500 · Balance 80,289 Row 2 · 2021-10-04 · Sale · Disposed 500 · Balance 79,789 F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2: This transaction was executed in multiple trades in prices ranging from $25.39 to $26.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2021-10-04 · Sale · Disposed 1,000 · Balance 78,789 F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3: This transaction was executed in multiple trades in prices ranging from $26.42 to $26.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.08 · Expires 2029-03-13 | Direct | 23,437 |
Reported balance
After 2021-10-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-04 · Exercise / conversion · Disposed 1,500 · Balance 23,437 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades in prices ranging from $25.39 to $26.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: This transaction was executed in multiple trades in prices ranging from $26.42 to $26.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $11.08 | $0.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 1,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,000 | $26.62 | $26,621.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $26.42 to $26.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 500 | $25.85 | $12,924.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.39 to $26.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,500 | $11.08 | $16,620.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,313 | $0.00 Strike: $11.08 | $0.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · derivative · entry 9 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,937 Underlying: Common Stock · 4,313 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,071 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · derivative · entry 8 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,048 Underlying: Common Stock · 7,071 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 200 | $27.67 | $5,534.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 6 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 11,184 | $27.41 | $306,559.03 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 5 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,989 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 4,313 | $11.08 | $47,788.04 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 7,071 | $4.31 | $30,476.01 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 116 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · derivative · entry 7 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,119 Underlying: Common Stock · 116 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 116 | $27.46 | $3,185.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 23:24 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 116 | $4.31 | $499.96 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 22:48 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 10,000 | $25.09 | $250,943.00 |
DisclosureSEC source: 0001567619-21-016820 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $24.95 to $25.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,235 Underlying: Common Stock · 1,500 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 400 | $23.52 | $9,406.00 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $23.49 to $23.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 11,100 | $22.96 | $254,862.66 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,189 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.48 to $23.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,500 | $4.31 | $6,465.00 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · derivative · entry 5 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,735 Underlying: Common Stock · 5,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 5,000 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 10,000 | $25.15 | $251,460.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $24.95 to $25.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 5,000 | $4.31 | $21,550.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 5,000 | $6.92 | $34,600.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 1,500 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 100 | $22.76 | $2,276.00 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,400 | $22.20 | $31,081.96 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,889 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.70 to $22.5450, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,500 | $6.92 | $10,380.00 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2021 Filed Jun 18, 2021 00:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 3,893 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-012384 · doc1.xml · derivative · entry 6 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 3,893 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 17, 2021 Filed Jun 18, 2021 00:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 3,893 | $22.49 | $87,539.94 |
DisclosureSEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $22.45 to $22.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 17, 2021 Filed Jun 18, 2021 00:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 3,893 | $6.92 | $26,939.56 |
DisclosureSEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 1,107 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-012384 · doc1.xml · derivative · entry 5 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,893 Underlying: Common Stock · 1,107 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,107 | $22.47 | $24,872.52 |
DisclosureSEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.45 to $22.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,107 | $6.92 | $7,660.44 |
DisclosureSEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:12 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-011941 · doc1.xml · derivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 1,500 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:12 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,500 | $20.22 | $30,333.15 |
DisclosureSEC source: 0001567619-21-011941 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $19.95 to $20.495, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:12 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,500 | $6.92 | $10,380.00 |
DisclosureSEC source: 0001567619-21-011941 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-009897 · doc1.xml · derivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 5,000 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 5,000 | $20.22 | $101,092.50 |
DisclosureSEC source: 0001567619-21-009897 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $19.97 to $20.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 11, 2021 Filed May 13, 2021 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 5,000 | $6.92 | $34,600.00 |
DisclosureSEC source: 0001567619-21-009897 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:10 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $19.52 | $0.00 |
DisclosureSEC source: 0001567619-21-005115 · doc1.xml · derivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:31 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-002869 · doc1.xml · derivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 5,000 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:31 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 5,000 | $20.74 | $103,696.50 |
DisclosureSEC source: 0001567619-21-002869 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.41 to $21.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:31 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 5,000 | $6.92 | $34,600.00 |
DisclosureSEC source: 0001567619-21-002869 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 22:35 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 7,750 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-20-021499 · doc1.xml · derivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,735 Underlying: Common Stock · 7,750 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 22:35 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 7,750 | $4.31 | $33,402.50 |
DisclosureSEC source: 0001567619-20-021499 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:02 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-20-004801 · doc1.xml · derivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2030-02-20 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.